摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-(1H-吡咯-1-基)苯甲胺 | 368869-95-8

中文名称
3-(1H-吡咯-1-基)苯甲胺
中文别名
3-(1H-吡咯-1-基)苄胺
英文名称
(3-(1H-pyrrol-1-yl)phenyl)methanamine
英文别名
3-(1H-Pyrrol-1-Yl)Benzylamine;(3-pyrrol-1-ylphenyl)methanamine
3-(1H-吡咯-1-基)苯甲胺化学式
CAS
368869-95-8
化学式
C11H12N2
mdl
MFCD03086143
分子量
172.23
InChiKey
XLBYUDUEHVKUKQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    138 °C
  • 密度:
    1.07±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.2
  • 重原子数:
    13
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.09
  • 拓扑面积:
    31
  • 氢给体数:
    1
  • 氢受体数:
    1

安全信息

  • 危险品标志:
    C
  • 安全说明:
    S26,S36/37/39
  • 危险类别码:
    R34
  • 海关编码:
    2933990090
  • 危险品运输编号:
    UN 3259

反应信息

点击查看最新优质反应信息

文献信息

  • 8-Benzyltetrahydropyrazino[2,1-<i>f</i>]purinediones: Water-Soluble Tricyclic Xanthine Derivatives as Multitarget Drugs for Neurodegenerative Diseases
    作者:Andreas Brunschweiger、Pierre Koch、Miriam Schlenk、Felipe Pineda、Petra Küppers、Sonja Hinz、Meryem Köse、Stefan Ullrich、Jörg Hockemeyer、Michael Wiese、Jag Heer、Christa E. Müller
    DOI:10.1002/cmdc.201402082
    日期:2014.5.9
    designed as tricyclic xanthine derivatives containing a basic nitrogen atom in the tetrahydropyrazine ring to improve water solubility. A library of 69 derivatives was prepared and evaluated in radioligand binding studies at adenosine receptor (AR) subtypes and for their ability to inhibit monoamine oxidases (MAO). Potent dual‐target‐directed A1/A2A adenosine receptor antagonists were identified. Several
    8-苄基取代的四氢吡嗪并[ 2,1 - f ]嘌呤二酮被设计为在四氢吡嗪环中包含碱性氮原子的三环黄嘌呤衍生物,以提高水溶性。制备了69种衍生物的文库,并在放射性配体结合研究中评估了腺苷受体(AR)亚型及其抑制单胺氧化酶(MAO)的能力。确定了有效的双靶标定向A 1 / A 2A腺苷受体拮抗剂。几种化合物显示出三重靶标抑制作用。最好的化合物之一是8-(2,4-二氯-5-氟苄基)-1,3-二甲基-6,7,8,9-四氢吡嗪并[2,1 - f ]嘌呤-2,4(1 H,3 H)-dione(72)(人类AR:K i  A 1 217 n M,A 2A 233 n M;IC 50 MAO-B:508 n M)。二氯化化合物36 [8-(3,4-二氯苄基)-1,3-二甲基-6,7,8,9-四氢吡嗪并[2,1 - f ]嘌呤-2,4(1 H,3 H)-二酮]被认为是大鼠中最佳的三靶标药物(K i  A 1
  • SUBSTITUTED PTERIDINES FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS
    申请人:Herdewijn Piet André Maurits Maria
    公开号:US20090318456A1
    公开(公告)日:2009-12-24
    Tri-substituted pteridines and tetra-substituted pteridines exhibit a significant and selective activity against certain types of viral infections, in particular they selectively inhibit the replication of the hepatitis C virus, and are useful for the prevention and treatment of such infections.
    三取代喹啉和四取代喹啉对某些类型的病毒感染表现出显著和选择性的活性,特别是它们选择性地抑制丙型肝炎病毒的复制,并可用于预防和治疗此类感染。
  • SUBSTITUTED PYRIDO(3,2-D) PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL INFECTIONS
    申请人:Herdewijn Piet Andre' Maurits Maria
    公开号:US20090253696A1
    公开(公告)日:2009-10-08
    This invention provides di-, tri- and tetra-substituted pyrido(3,2-d)pyrimidine derivatives with specific substituting patterns, their pharmaceutically acceptable salts, N-oxides, solvates, pro-drugs and enantiomers, possessing unexpectedly desirable pharmaceutical properties, in particular being highly active antiviral agents. The invention also provides use of such derivatives in the treatment of viral infections and pathologic conditions associated therewith, including hepatitis C.
    这项发明提供了具有特定取代模式的二、三和四取代吡啶并[3,2-d]嘧啶衍生物,其药学上可接受的盐、N-氧化物、溶剂合物、前药和对映体,具有意外地理想的药理特性,特别是作为高活性抗病毒剂。该发明还提供了利用这些衍生物治疗病毒感染及相关病理状况,包括丙型肝炎的用途。
  • [EN] 4- BROMO - 5 - (2- CHLORO - BENZOYLAMINO) - 1H - PYRAZOLE - 3 - CARBOXYLIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES<br/>[FR] DERIVES AMIDES DE L'ACIDE CARBOXYLIQUE DE 4- BROMO - 5 - (2- CHLORO - BENZOYLAMINO) - 1H - PYRAZOLE 3 ET COMPOSES ASSOCIES EN TANT QU'ANTAGONISTES DE RECEPTEUR DE B1 DE LA BRADYKININE POUR LE TRAITEMENT DE MALADIES INFLAMMATOIRES
    申请人:ELAN PHARM INC
    公开号:WO2004098589A1
    公开(公告)日:2004-11-18
    Disclosed are compounds of formula I and II that are bradykinin B1 receptor antagonists and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B1 receptor. Certain of the compounds exhibit increased potency and are also expected to exhibit increased duration of action.
    公开的是化合物I和II的结构式,它们是激肽酶B1受体拮抗剂,适用于治疗哺乳动物中由激肽酶B1受体介导的疾病,或缓解与疾病状况相关的不良症状。其中某些化合物表现出增强的效力,并且预计还将表现出延长作用的特性。
  • [EN] PYRIMIDINE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE<br/>[FR] COMPOSÉS PYRIMIDINE QUI INHIBENT LA KINASE DU LYMPHOME ANAPLASIQUE
    申请人:AMGEN INC
    公开号:WO2011143033A1
    公开(公告)日:2011-11-17
    Compounds of Formula I are useful inhibitors of anaplastic lymphoma kinase. Compounds of Formula I have the following structure: where the definitions of the variables are provided herein.
    Formula I的化合物是一种有用的间变性淋巴瘤激酶抑制剂。Formula I的化合物具有以下结构:变量的定义在此提供。
查看更多